NCT06017258View on ClinicalTrials.gov

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 22, 2023

Primary Completion Date

August 22, 2026

Study Completion Date

August 22, 2026

Conditions
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Interventions
BIOLOGICAL

CD371-specific/YSNVz/I-18 CAR T cells

Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All protocol activites), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER